Evox partnership with Takeda Pharmaceutical for rare disease
Evox Therapeutics Ltd, a leading exosome therapeutics company, announced the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited. The... Read More
What are the difference between FDA 483 and Warning Letter?
Posted on27 Mar 2020
Comments0
483 observation or FDA 483 and warning letter seems to be same, nut there is difference between the FDA form 483 and... Read More
New Drug Approval Case Study: USFDA approval of Zeposia, delayed market launch likely due to COVID-19
U.S. Food and Drug Administration (FDA) has approved ZEPOSIA® (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple... Read More
AstraZeneca and Silence Therapeutics co-development siRNA therapeutics
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular (CV),... Read More
US FDA halts the regular plant inspection due to Covid-19 spread
The US FDA announced that it will no longer be able to inspect domestic production facilities in wake of risk posed by... Read More
Gilead’s Epclusa receives US FDA approval to treat chronic hepatitis C infection for children ages 6 & older
US FDA has approved a supplemental New Drug Application (sNDA) for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) for the treatment... Read More
A case based understanding in co-development deal
In a Co-Development Agreement the intellectual property is typically licensed by the licensor to the alliance partner, and as well, the two... Read More
ProBiotix Health has signed a distribution licensing agreement with Velinoff Pharma in Bulgaria
UK-based life sciences business OptiBiotix Health said that its unit ProBiotix Health has signed a licensing agreement with Bulgarian pharmaceutical marketing company... Read More
RIBOMIC – AJU Pharma licensing deal for RBM-007 in age-related macular degeneration
Posted on20 Mar 2020
Comments0
RBOMIC has finalized the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company. This deal is for RBM-007 licensing agreement for... Read More
Regeneron, Sanofi initiates clinical trial in Kevzara to treat COVID-19
Regeneron Pharmaceuticals and Sanofi have started a clinical programme evaluating Kevzara (sarilumab) in patients hospitalized with severe coronavirus (COVID-19) infection. Kevzara is... Read More